Population screening in the age of genomic medicine

New England Journal of Medicine

Volumn 348, Issue 1, 2003, Pages 50-58

  Khoury, Muin J ^a   McCabe, Linda L ^b,c   McCabe, Edward R B ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; BLOOD CLOTTING FACTOR 5 LEIDEN;

CYSTIC FIBROSIS; ETHICS; GENETIC SUSCEPTIBILITY; GENOMICS; HEALTH CARE POLICY; HEMOCHROMATOSIS; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; LEGAL ASPECT; MASS SCREENING; NEWBORN SCREENING; ONSET AGE; PRIORITY JOURNAL; REVIEW; SOCIAL ASPECT; TAY SACHS DISEASE;

GENETICS AND REPRODUCTION;

ADULT; CHILD; CYSTIC FIBROSIS; FACTOR V; FEMALE; GENETIC SCREENING; GENOMICS; HEMOCHROMATOSIS; HETEROZYGOTE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; POINT MUTATION; TAY-SACHS DISEASE;

EID: 0037413486     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra013182     Document Type: Review

References (73)

1. Juengst ET. "Prevention" and the goals of genetic medicine. Hum Gene Ther 1995;6:1595-605.
2. Ransohoff DF, Sandler RS. Screening for colorectal cancer. N Engl J Med 2002;346:40-4.
3. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public Health Papers No. 34. Geneva: World Health Organization, 1968.
4. Wald NJ. The definition of screening. J Med Screen 2001;8:1.
5. Wilfond BS, Thomson EJ. Models of public health genetics policy development. In: Khoury MJ, Burke W, Thomson EJ, eds. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press, 2000:61-82.
6. Committee for the Study of Inborn Errors of Metabolism. Genetic Screening: Programs, Principles, and Research. Washington, D.C.: National Academy of Sciences, 1975.
7. McCabe LL, Therrell BL Jr, McCabe ERB. Newborn screening: rationale for a comprehensive, fully integrated public health system. Mol Genet Metab (in press).
8. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
9. Chace DH, Hillman SL, Van Hove JL, Naylor EW. Rapid diagnosis of MCAD deficiency: Quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 1997;43:2106-13.
10. Andresen BS, Dobrowolski SF, O'Reilly L, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: Identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-18.
11. McCabe ERB, Huang S-Z, Seltzer WK, Law ML. DNA microextraction from dried blood spots on filter paper blotters: Potential applications to newborn screening. Hum Genet 1987;75:213-6.
12. Jinks DC, Minter M, Tarver DA, Vanderford M, Hejtmancik JF, McCabe ERB. Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 1989;81:363-6.
13. Descartes M, Huang Y, Zhang Y-H, et al. Genotypic confirmation from the original dried blood specimens in a neonatal hemoglobinopathy screening program. Pediatr Res 1992;31:217-21.
14. Zhang Y-H, McCabe LL, Wilborn M, Therrell BL Jr, McCabe ERB. Application of molecular genetics in public health: Improved follow-up in a neonatal hemoglobinopathy screening program. Biochem Med Metab Biol 1994;52:27-35.
15. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial. N Engl J Med 1986;314:1593-9.
16. Consensus Development Panel. Newborn Screening for Sickle Cell Disease and Other Hemoglobinopathies. NIH Consensus Statement. Vol. 6. No. 9. Bethesda, Md.: NIH Office of Medical Applications of Research, 1987:1-22.
17. American Academy of Pediatrics Committee on Genetics. Newborn screening fact sheets. Pediatrics 1989;83:449-64.
18. Burrow GN, Dussault JH, eds. Neonatal Thyroid Screening. New York: Raven Press, 1980:155.
19. McCabe ERB, McCabe L, Mosher GA, Allen RJ, Berman JL. Newborn screening for phenylketonuria: Predictive validity as a function of age. Pediatrics 1983;72:390-8.
20. Holtzman C, Slazyk WE, Cordero JF, Hannon WH. Descriptive epidemiology of missed cases of phenylketonuria and congenital hypothyroidism. Pediatrics 1986;78:553-8.
21. Dequeker E, Cassiman J-J. Quality evaluation of data interpretation and reporting. Am J Hum Genet 2001;69:Suppl;438. abstract.
22. Mehl AL, Thomson V. The Colorado Newborn Hearing Screening Project, 1992-1999: On the threshold of effective population-based universal newborn hearing screening. Pediatrics 2002;109:134. abstract.
23. Cohn ES, Kelley PM. Clinical phenotype and mutations in connexin 26(DFNB1/GJB2), the most common cause of childhood hearing loss. Am J Med Genet 1999;89:130-6.
24. Morrell RJ, Kim HJ, Hood LJ, et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. N Engl J Med 1998;339:1500-5.
25. McCabe ERB, McCabe LL. State-of-the-art for DNA technology in newborn screening. Acta Paediatr Suppl 1999;88:58-60.
26. Newborn Screening Task Force. Serving the family from birth to the medical home: Newborn screening: A blueprint for the future - A call for a national agenda on state newborn screening programs. Pediatrics 2000;106:389-422.
27. Reardon MC, Hammond KB, Accurso FJ, et al. Nutritional deficits exist before 2 months of age in some infants with cystic fibrosis identified by screening test. J Pediatr 1984;105:271-4.
28. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics 2001;107:1-13.
29. Hassemer DJ, Laessig RH, Hoffman GL, Farrell PM. Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. Pediatr Pulmonol Suppl 1991;7:76-83.
30. Seltzer WK, Accurso F, Fall MZ, et al. Screening for cystic fibrosis: Feasibility of molecular genetic analysis of dried blood specimens. Biochem Med Metab Biol 1991;46:105-9.
31. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): Comparison of screening protocols. Am J Hum Genet 1993;52:616-26.
32. Kant JA, Mifflin TE, McGlennen R, Rice E, Naylor E, Cooper DL. Molecular diagnosis of cystic fibrosis. Clin Lab Med 1995;15:877-98.
33. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th Ed. Vol. 2. New York: McGraw-Hill, 2001:2297-326.
34. Matsubara Y, Narisawa K, Tada K, et al. Prevalence of K329E mutation in medium-chain acyl-CoA dehydrogenase gene determined from Guthrie cards. Lancet 1991;338:552-3.
35. Wilcken B, Travert G. Neonatal screening for cystic fibrosis: Present and future. Acta Paediatr Suppl 1999;88:33-5.
36. Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 1999;14:Suppl 1:S4-S8.
37. Kaback MM. Population-based genetic screening for reproductive counseling: The Tay-Sachs disease model. Eur J Pediatr 2000;159:Suppl 3:S192-S195.
38. Mitchell JJ, Capua A, Clow C, Scriver CR. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and β-thalassemia disease carriers in high schools. Am J Hum Genet 1996;59:793-8.
39. McCabe L. Efficacy of a targeted genetic screening program for adolescents. Am J Hum Genet 1996;59:762-3.
40. Genetic testing for cystic fibrosis: National Institutes of Health Consensus Development Conference statement on genetic testing for cystic fibrosis. Arch Intern Med 1999;159:1529-39.
41. Grody WW, Desnick RJ. Cystic fibrosis population carrier screening: Here at last - Are we ready? Genet Med 2001;3:87-90.
42. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med 2001;3:149-54.
43. Mak V, Zielenski J, Tsui L-C, et al. Proportion of cystic fibrosis gene mutations not detected by routine testing in men with obstructive azoospermia. JAMA 1999;281:2217-24.
44. Raman V, Clary R, Siegrist KL, Zehnbauer B, Chatila TA. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 2002;109:136-7. abstract.
45. Wang XJ, Moylan B, Leopold DA, et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 2000;284:1814-9.
46. Goel V. Appraising organised screening programmes for testing for genetic susceptibility to cancer. BMJ 2001;322:1174-8.
47. Khoury MJ, Burke W, Thomson EJ. Genetics and public health: a framework for the integration of human genetics into public health practices. In: Khoury MJ, Burke W, Thomson EJ, eds. Genetics and Public Health in the 21st Century: Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press, 2000:3-24.
48. Burke W, Coughlin SS, Lee NC, Weed DL, Khoury MJ. Application of population screening principles to genetic screening for adult-onset conditions. Genet Test 2001;5:201-11.
49. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-5.
50. Collins FS. Keynote speech at the Second National Conference on Genetics and Public Health, December 1999. Atlanta: Office of Genetics & Disease Prevention, 2000. (Accessed December 6, 2002, at http://www.cdc.gov/genomics/info/conference/intro.htm.)
51. Cogswell ME, Burke W, McDonnell SM, Franks AL. Screening for hemochromatosis: A public health perspective. Am J Prev Med 1999;16:134-40.
52. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening. JAMA 1998;280:172-8.
53. EASL International Consensus Conference on Hemochromatosis. III. Jury document. J Hepatol 2000;33:496-504.
54. Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ. Contribution of different HFE genotypes to iron overload disease: A pooled analysis. Genet Med 2000;2:271-7.
55. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-8.
56. Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-22.
57. Brown AS, Gwinn M, Cogswell ME, Khoury MJ. Hemochromatosis-associated morbidity in the United States: An analysis of the National Hospital Discharge Survey, 1979-1997. Genet Med 2001;3:109-11.
58. Yang Q, McDonnell SM, Khoury MJ, Cono J, Parrish RG. Hemochromatosis-associated mortality in the United States from 1979 to 1992: An analysis of Multiple-Cause Mortality Data. Ann Intern Med 1998; 129:946-53.
59. Imperatore G, Valdez R, Burke W. Case study: hereditary hemochromatosis. In: Khoury MJ, Little J, Burke W, eds. Human Genome Epidemiology: Scientific Foundation for Using Genetic Information to Improve Health and Prevent Disease. New York: Oxford University Press (in press).
60. Greenberg DL, Davie EW. Introduction to hemostasis and the vitamin K-dependent coagulation factors. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th Ed. Vol. 3. New York: McGraw-Hill, 2001:4293-326.
61. Esmon CT. Anticoagulation protein C/thrombomodulin pathway. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8th Ed. Vol. 3. NewYork: McGraw-Hill, 2001:4327-43.
62. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
63. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening. JAMA 1997;277:1305-7.
64. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-8.
65. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - Pooled analysis of 8 case-controlled studies including 2310 cases and 3204 controls. Thromb Haemost 2001;86:809-16. [Erratum, Thromb Haemost 2001;86:1598.]
66. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
67. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-30.
68. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-48.
69. Committee on Genetics. Molecular genetic testing in pediatric practice: A subject review. Pediatrics 2000;106:1494-7.
70. Nelson RM, Botkjin JR, Kodish ED, et al. Ethical issues with genetic testing in pediatrics. Pediatrics 2001;107:1451-5.
71. The American Society of Human Genetics. Statement on informed consent for genetic research. Am J Hum Genet 1996;59:471-4.
72. McCabe ERB. Clinical genetics: Compassion, access, science, and advocacy. Genet Med 2001;3:426-9.
73. Physicians' Desk Reference. 56th Ed. Montvale, N.J.: Medical Economics, 2002.